How Clinicians Manage Their Patients Who May Need Antithrombotic Care

NCT ID: NCT05923658

Last Updated: 2023-07-21

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 2500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-10-01
• Study Completion Date: 2023-12-01

Brief Summary

This study aims to assess the knowledge and provide an opportunity for education to clinician attendees of the Canadian Cardiovascular Congress (CCC) meeting using a series of simulated patient case scenarios.

Detailed Description

Health conditions requiring antithrombotic therapy are highly prevalent in Canada, contributing substantially to healthcare costs and patient quality of life. For example, over 60,000 Canadians will experience a heart attack per year.1 Alarming statistics such as this warrant appropriate treatment approaches from clinicians who specialize in cardiovascular conditions. The CCC is a national conference during which individuals with an interest or expertise in cardiovascular health from across the country attend. Leveraging this unique opportunity by implementing a simple educational endeavour during the 2023 event can provide instrumental insights on the most appropriate treatments recommended from the latest clinical practice guidelines to a wide set of practitioners; this could, in turn, potentially improve patient health outcomes.

This endeavour will take place at a set date from October 25th to 29th, 2023. Attendees of the CCC who approach a booth set up by the lead investigator of this project will be presented with the study letter of information and consent form on a tablet (i.e., an iPad). After providing an electronic informed consent to participate, a series of patient case scenarios that require antithrombotic care and therapy will be shown. For each case scenario, the attendee (now, considered a study participant) will be asked to indicate the treatment approach that he/she would choose. And finally, after reviewing all case scenarios and selecting the best treatment approach to his/her knowledge, the participant will be asked to provide an email address (which could be an anonymized one) to send the most appropriate treatment approaches for each case scenario. This last step allows the participant an educational opportunity to learn what the best practice approach is based on the most up-to-date clinical practice guidelines. The approximate total duration of the study is one-hour in total.

Conditions

Thrombosis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Any clinician (i.e., licensed medical doctor, nurse practitioner) attending the CCC's 2023 event from October 25th-29th, 2023 will be included in this endeavour so long as they have the ability to provide informed consent (i.e., can read, write, and understand the English language).

Exclusion Criteria

• None

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Anthony Tang

OTHER

Sponsor Role: lead

Responsible Party

Anthony Tang

Professor and Scientific Director

Responsibility Role: SPONSOR_INVESTIGATOR

Central Contacts

Nellie Kamkar, MSc

Role: CONTACT

Nellie.Kamkar@lhsc.on.ca

1-519-661-2111 Ext. 86013

Tina Khazaee, MSc

Role: CONTACT

tina.khazaee@lhsc.on.ca

1-519-661-2111 Ext. 86013

References

Antiperovitch P, Liu I, Mokhtar AT, Tang A. Evaluating Large Language Models in Cardiovascular Antithrombotic Care: Performance, Accuracy, and Implications for Clinical Practice. Can J Cardiol. 2025 Aug;41(8):1584-1591. doi: 10.1016/j.cjca.2025.04.008. Epub 2025 Apr 15.

Reference Type: DERIVED

PMID: 40239865 (View on PubMed)

Other Identifiers

Antithrombotic Care at the CCC

Identifier Type: -

Identifier Source: org_study_id